{
  "id": "5a7238d32dc08e987e000009",
  "type": "list",
  "question": "Which two cotransporters are inhibited by sotagliflozin?",
  "ideal_answer": "Sotagliflozin works by inhibiting sodium-glucose cotransporter 1 (SGLT1) and sodium-glucose cotransporter 2 (SGLT2). It is used for treatment of diabetes.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
    "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
    "http://www.ncbi.nlm.nih.gov/pubmed/28387957",
    "http://www.ncbi.nlm.nih.gov/pubmed/28872070",
    "http://www.ncbi.nlm.nih.gov/pubmed/28899222",
    "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
    "http://www.ncbi.nlm.nih.gov/pubmed/26484403",
    "http://www.ncbi.nlm.nih.gov/pubmed/25759591",
    "http://www.ncbi.nlm.nih.gov/pubmed/25690134"
  ],
  "snippets": [
    {
      "text": "The present study used molecular docking by Autodock4.2 using our \"Click-By-Click\"-protocol, Ligplot1.4.3 and \"change in accessible surface area (\u0394ASA)-calculations\" to investigate the binding of two investigational anti-diabetic drugs, Ertugliflozin and Sotagliflozin to an established target (SGLT2) and a research target (human brain AChE).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28387957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SGLT2 inhibitors such as canagliflozin and sotagliflozin (a SGLT1/SGLT2 dual inhibitor) also have a mild or moderate intestinal and renal SGLT1 inhibitory effect because of their relatively weak selectivity for SGLT2 over SGLT1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Hydrogen-bonded structures and interaction energies in two forms of the SGLT-2 inhibitor sotagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872070",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 2 studies with the SGLT2 inhibitor empagliflozin and the dual SGLT1 and SGLT2 inhibitor sotagliflozin, which acts in the gut and the kidney, have demonstrated reductions in A1C, weight, and glucose variability without an increased incidence of hypoglycemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484403",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2 and intestinal SGLT1. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759591",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AREAS COVERED: Herein, the authors focus specifically on sotagliflozin (LX4211), the first-in-class dual SGLT1/SGLT2 inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite a weaker effect on UGE than selective SGLT2 inhibitors, sotagliflozin is as effective as SGLT2 inhibitors on HbA1C reduction, with a similar safety profile in short-term studies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, sotagliflozin (LX4211) has been developed as a dual inhibitor of SGLT1 and SGLT2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25690134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.RESEARCH DESIGN AND METHODS: We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or placebo in a randomized, double-blind trial assessing safety, insulin dose, glycemic control, and other metabolic parameters over 29 days of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved glycemic control and the CGM profile with bolus insulin dose reduction, weight loss, and no increased hypoglycemia in type 1 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite a weaker effect on UGE than selective SGLT2 inhibitors, sotagliflozin is as effective as SGLT2 inhibitors on HbA1C reduction, with a similar safety profile in short-term studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, sotagliflozin (LX4211) has been developed as a dual inhibitor of SGLT1 and SGLT2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25690134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved glycemic control and the CGM profile with bolus insulin dose reduction, weight loss, and no increased hypoglycemia in type 1 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AREAS COVERED Herein, the authors focus specifically on sotagliflozin (LX4211), the first-in-class dual SGLT1/SGLT2 inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "sodium-glucose cotransporter 1, sodium-glucose cotransporter 2"
}